Do genetic polymorphisms alter patient response to inhaled bronchodilators?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 9, 2014, Pages 1231-1240

  Lima, John J ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Adrenergic receptor; Asthma; Bronchodilator; Drug; Gene; Heritability; Heterogeneity; Pharmacogenetic; Polymorphisms; Response

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; LONG ACTING BETA AGONIST; SHORT ACTING BETA AGONIST; UNCLASSIFIED DRUG; ADRB2 PROTEIN, HUMAN; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR; DELAYED RELEASE FORMULATION;

ASTHMA; BETA2 ADRENERGIC RECEPTOR GENE; DISEASE EXACERBATION; DRUG SAFETY; GENE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; DELAYED RELEASE FORMULATION; GENETICS; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PHARMACOGENETICS;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY FUNCTION TESTS;

EID: 84906050804     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.939956     Document Type: Review

References (88)

1. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007;448:470-3
2. Himes BE, Hunninghake GM, Baurley JW, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009;84:581-93
3. Hancock DB, Romieu I, Shi M, et al. Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children. PLoS Genet 2009;5:e1000623
4. Mathias RA, Grant AV, Rafaels N, et al. A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol 2010;125:336-46
5. Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med 2010;362:36-44
6. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010;363:1211-21
7. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24
8. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23
9. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382-9; e1-13
10. Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One 2012;7:e36631
11. Patrawalla P, Kazeros A, Rogers L, et al. Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population. PLoS One 2012;7:e44540
12. Kim TB, Jang AS, Kwon HS, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J 2013;41(6):1308-14
13. Ober C, Vercelli D. Gene-environment interactions in human disease: nuisance or opportunity? Trends Genet 2011;27:107-15
14. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43
15. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
16. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120:S94-138
17. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
18. Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1993;1179:171-88
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87
20. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J 2011;11:383-92
21. Thomsen SF, van der Sluis S, Kyvik KO, et al. Estimates of asthma heritability in a large twin sample. Clin Exp Allergy 2010;40:1054-61
22. Klimentidis YC, Vazquez AI, de Los Campos G, et al. Heritability of pulmonary function estimated from pedigree and whole-genome markers. Front Genet 2013;4:174
23. McGeachie MJ, Wu AC, Chang HH, et al. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J 2013;13:306-11
24. Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 2006;15:326-31
25. Ortega VE, Peters SP. Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol 2010;10:246-53
26. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996;335:841-7
27. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6
28. Suissa S, Ernst P, Spitzer WO. Asthma deaths in New Zealand. BMJ 1992;305:889; author reply 90
29. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93
30. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30
31. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12
32. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603
33. Subbarao P, Ratjen F. Beta2-agonists for asthma: the pediatric perspective. Clin Rev Allergy Immunol 2006;31:209-18
34. Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet 2006;367:286-8
35. Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997;156:688-95
36. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4
37. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7
38. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008;CD006363
39. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
40. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2010. Available from: www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm200776.htm [Accessed 16 June 2014]; Referenced June 24, 2014
41. Kramer JB. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. N Engl J Med 2009;360:1592-5
42. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71
43. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009;22:9-19
44. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42
45. Ortega VE, Wechsler ME. Asthma pharmacogenetics: responding to the call for a personalized approach. Curr Opin Allergy Clin Immunol 2013;13:399-409
46. Salpeter SR. An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids. Expert Opin Drug Saf 2010;9:407-19
47. Sears MR. Safe use of long-acting beta-agonists: what have we learnt? Expert Opin Drug Saf 2011;10:767-78
48. Hawkins GA, Tantisira K, Meyers DA, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006;174:1101-9
49. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Published erratum appears in Biochemistry 1994 Nov 29;33(47):14368
50. Biochemistry 1994;33:9414-19
51. Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:25-33
52. Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-S62
53. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8
54. Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65:519-25
55. Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005;171:563-70
56. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [In Process Citation]. Proc Natl Acad Sci USA 2000;97:10483-8
57. Silverman EK, Kwiatkowski DJ, Sylvia JS, et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 2003;112:870-6
58. Taylor DR, Epton MJ, Kennedy MA, et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005;172:700-3
59. Hall IP, Blakey JD, Al Balushi KA, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British. 1958 birth cohort: a genetic association study. Lancet 2006;368:771-9
60. Tsai HJ, Shaikh N, Kho JY, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 2006;119:547-57
61. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12
62. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998;11:589-93
63. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta (2) adrenoceptor polymorphism. Thorax 2000;55:762-7
64. Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173:519-26
65. Lee DK, Currie GP, Hall IP, et al. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004;57:68-75
66. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370:2118-25
67. Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010;181:676-87
68. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotypestratified, randomised, placebocontrolled, crossover trial. Lancet 2009;374:1754-64
69. Bonini M, Permaul P, Kulkarni T, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med 2013;188:1407-12
70. Ambrose HJ, Lawrance RM, Cresswell CJ, et al. Effect of beta2-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting beta2-adrenergic agonist response. Respir Res 2012;13:37
71. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36:391-8
72. Verberne AA, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998;158:213-19
73. Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006;61:940-4
74. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics 2013;14:1965-71
75. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med 2014;2:204-13
76. Moore PE, Ryckman KK, Williams SM, et al. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Pediatr Pulmonol 2009;44:649-54
77. Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics 2010;20:351-8
78. Tantisira KG, Small KM, Litonjua AA, et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005;14:1671-7
79. Poon AH, Tantisira KG, Litonjua AA, et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008;18:373-82
80. Litonjua AA, Lasky-Su JA, Schneiter K, et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008;178(7):688-94
81. Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 2011;183:449-54
82. Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014;14(1):41-7
83. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS21 as a novel bronchodilator response gene. PLos Genet 2012;8(7):e1002824
84. Padhukasahasram B, Yang JJ, Levin AM, et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J 2014. [Epub ahead of print]
85. Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014;14:41-7
86. Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol 2014;133:370-8; e15
87. Urban TJ. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 2013;14:345-8
88. Wu AC, Himes BE, Lasky-Su J, et al. Development of a Pharmacogenetic Predictive Test in asthma: proof of concept. Pharmacogenet Genomics 2010;20:86-93